Comparative Pharmacology
Head-to-head clinical analysis: MINASTRIN 24 FE versus NORMINEST FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MINASTRIN 24 FE versus NORMINEST FE.
MINASTRIN 24 FE vs NORMINEST FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of an estrogen (ethinyl estradiol) and a progestin (norethindrone acetate) that inhibits gonadotropin release from the pituitary, suppressing ovulation, thickening cervical mucus, and altering endometrial receptivity.
Combination oral contraceptive containing norethindrone acetate (progestin) and ethinyl estradiol (estrogen). Inhibits ovulation via suppression of gonadotropins (FSH, LH). Increases cervical mucus viscosity, reducing sperm penetration. Norethindrone acetate is metabolized to norethindrone, which binds to progesterone receptors; ethinyl estradiol binds to estrogen receptors, providing contraceptive effect and cycle control.
One tablet orally once daily for 24 weeks, followed by 4 placebo tablets. Each tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol for 21 days, then 1 mg norethindrone acetate and 0.75 mg ferrous fumarate for 7 days.
1 tablet orally once daily, starting on day 1 of menstrual cycle; each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg (21 active tablets) followed by 7 ferrous fumarate tablets.
None Documented
None Documented
Norethindrone: 7-8 hours; ethinyl estradiol: 13-27 hours. Clinical context: Steady-state achieved within 5-10 days; half-life supports once-daily dosing.
Norethindrone: 7-8 hours; ethinyl estradiol: 13-14 hours. Clinical context: steady-state in 5-7 days.
Urine (primarily as glucuronide conjugates; ethinyl estradiol and norethindrone metabolites) and feces. Approximately 40% of norethindrone metabolites are excreted in urine and 60% in feces. Ethinyl estradiol is excreted as glucuronide and sulfate conjugates in urine (40%) and feces (60%).
Renal 60-80% as metabolites, fecal 20-30% via bile, unchanged drug <5%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive